首页 > R&D Systems > R&D Systems/Human Pappalysin-1/PAPP-A Antibody/AF2487/100 ug

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

R&D Systems/Human Pappalysin-1/PAPP-A Antibody/AF2487/100 ug

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

AF2487-100ug

品牌：

R&D Systems

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Species ReactivityHumanSpecificityDetects human Pappalysin‑1/PAPP‑A in direct ELISAs and Western blots. In direct ELISAs and Western blots, less than 5% cross-reactivity with recombinant human PAPP-A2 is observed.SourcePolyclonal Goat IgGPurificationAntigen Affinity-purifiedImmunogenMouse myeloma cell line NS0-derived recombinant human Pappalysin‑1/PAPP‑AGlu82-Asp1214 Accession # Q13219FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.LabelUnconjugated Western Blot0.1 µg/mLSee belowImmunoprecipitation25 µg/mLConditioned cell culture medium spiked with Recombinant Human Pappalysin‑1/PAPP-A (Catalog # 2487-ZN), see our available Western blot detection antibodiesReconstitutionReconstitute at 0.2 mg/mL in sterile PBS.ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °CStability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution.6 months, -20 to -70 °C under sterile conditions after reconstitution. References:Boldt, H.B. et al. (2001) Biochem. J. 358:359.Fialova L. and I.M. Malbohan (2002) Bratisl. Lek. Listy 103:194.Laursen, L.S. et al. (2001) FEBS Lett. 504:36.Conover, C.A. et al. (2004) Development 131:1187.Boldt, H.B. et al. (2004) J. Biol. Chem. 279:38525.Long Name:Pregnancy-associated Plasma Protein 1Entrez Gene IDs:5069 (Human)Alternate Names:ASBABP2; DIPLA1; EC 3.4.24.79; IGFBP-4ase; IGFBP-4aseaspecific BCL2 ARE-binding protein 2; IGF-dependent IGFBP-4 protease; insulin-like growth factor-dependent IGF binding protein-4 protease; Insulin-like growth factor-dependent IGF-binding protein 4 protease; PAPA; PAPPA; PAPPA1; PAPP-A1; PAPP-Adifferentially placenta 1 expressed protein; Pappalysin1; Pappalysin-1; pregnacy-associated plasma protein A; Pregnancy-associated plasma protein A; pregnancy-associated plasma protein A, pappalysin 1Background:Pappalysins belong to a fifth family of metzincins that consists of ADAMs/ADAMTSs, MMPs, astacins and serrylysins (1). PAPP-A is an important pregnancy protein and increases in plasma by a factor of about 150 during pregnancy as compared to the nonpregnant state. PAPP-A is also a major marker of Down syndrome in the first trimester of pregnancy because maternal serum levels of PAPP-A are significantly reduced when a fetus affected by Down syndrome is present (2). PAPP-A cleaves Insulin-like Growth Factor-Binding Protein-4 and -5 (IGFBP-4 and -5) at a single site, resulting in the release of bioactive IGF (3). Lack of IGFBP-4 cleavage in embryonic fibroblasts derived from PAPP-A knockout mice indicates that PAPP-A functions as a physiological IGFBP-4 protease (4). Three Lin12-Notch repeats (LNR) in the PAPP-A protein bind Ca2+ and are required for the cleavage of IGFBP-4, not IGFBP-5, by PAPP-A (5). The C-terminal LNR (residues 1476 to 1503) is not present in rhPAPP-A (residues 82 to 1214), which starts at the N-terminus of the mature chain and ends before the five Sushi (SCR) modules. As an active protease, rhPAPP-A cleaves IGFBP-5, which can be inhibited by 1,10-phenanthroline.

R&D Systems位于美国的明尼苏达州，一直致力于生物制品的开发与生产。公司成立之初主要生产用于医院及临床应用的血控品。1997年，公司推出第一个产品--富血小板血浆质控品；1981年，公司成为全球第二家生产含血小板全血控品的供应商。40多年的发展中，R&D Systems仍持续开发各种血控品产品。

1985年，作为公司推出的第一个科研试剂产品，也是全球第一家将该产品进行商业化生产的产品，R&D Systems成功上市了TGF-beta1蛋白。作为胞外信号分子，TGF-beta1蛋白在多种细胞中进行表达，并作为胞外信号分子参与免疫功能，细胞增殖和细胞分化等生物学过程。该产品推出后，公司陆续从生物材料中纯化了几种细胞因子产品并推向市场。

天然蛋白类产品的成功推广，加速了R&D Systems在细胞因子市场的开拓。公司于1985年形成Growth Factor事业部（现Biotechnology事业部）。Biotechnology事业部的目标是生产和营销重组人细胞因子。与天然来源提取蛋白相比较，DNA重组技术生产的蛋白产品其成本更低，产量更高，完全摆脱原料的限制。1989年，Biotechnology事业部开始开发抗细胞因子的单克隆和多克隆抗体，并于1990年开发了第一个ELISA试剂盒。

2014年2月10日，R&D Systems的母公司宣布命名为Bio-Techne. Bio-Techne旗下包括R&D Systems, Novus Biologicals, BiosPacific, Tocris Bioscience, Boston Biochem和Bionostics。